Skip to content
Screener

PTC Therapeutics PTCT Gross Profit

Discontinued — last reported Q4 '19

Gross Profit at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$786.91M+16.5%
ALN
Alnylam PharmaceuticalsALNY
$992.69M+57.2%
Biogen logo
BiogenBIIB
$1.96B-4.0%
uniQure logo
uniQureQURE
$5.49M+19.2%

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$5.78B+41.9%
Enterprise value$5.34B+54.9%
P/E7.1×—
P/S7×+4.7×

Profitability

See full
Gross margin96%—
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%—
Debt / equity372.3×—
Current ratio2.4×-1.5×

Where this comes from

Calculated from PTC Therapeutics’s reported figures.

$96.5Mtotal revenue−$3.5Mtotal cost of revenue=$92.92M

The source filing: PTC Therapeutics’s 10-K, filed February 22, 2022. Open the filing →

Filed
Feb 22, 2022, 4:36 PM EST
Fiscal year
FY2021
Accession
0001070081-22-000011

FAQ

What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.